(IRWD) Ironwood Pharmaceuticals - Ratings and Ratios
Linaclotide, Plecanatide
IRWD EPS (Earnings per Share)
IRWD Revenue
Description: IRWD Ironwood Pharmaceuticals August 18, 2025
Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) is a US-based biotechnology company. To evaluate its investment potential, we need to analyze its financial performance, particularly its income statement. The yearly Income Tax Expense is a crucial metric that can impact the companys net income.
From a fundamental analysis perspective, Ironwood Pharmaceuticals has a market capitalization of $159.59M USD, indicating a relatively small-cap company. The forward Price-to-Earnings (P/E) ratio is 12.33, suggesting that investors are expecting future earnings growth. However, the Return on Equity (RoE) is not available, which might indicate that the company is not generating profits or has a complex equity structure.
Key economic drivers for Ironwood Pharmaceuticals include the development and commercialization of its pharmaceutical products, particularly in the gastrointestinal therapeutic area. The companys revenue growth, R&D expenses, and SG&A costs are essential KPIs to monitor. Additionally, the companys cash position, debt levels, and cash flow generation are critical in determining its financial health and ability to invest in future growth opportunities.
To further assess IRWDs investment potential, we should examine its revenue growth rate, gross margin, and operating expenses as a percentage of revenue. We should also consider the competitive landscape, regulatory environment, and industry trends that may impact the companys future performance. A thorough analysis of these factors will help us determine whether IRWD is an attractive investment opportunity.
IRWD Stock Overview
| Market Cap in USD | 312m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2010-02-03 |
IRWD Stock Ratings
| Growth Rating | -78.5% |
| Fundamental | 50.9% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -63.4% |
| Analyst Rating | 3.0 of 5 |
IRWD Dividends
Currently no dividends paidIRWD Growth Ratios
| Growth Correlation 3m | 91.8% |
| Growth Correlation 12m | -58% |
| Growth Correlation 5y | -78.7% |
| CAGR 5y | -46.23% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.48 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.94 |
| Sharpe Ratio 12m | -1.71 |
| Alpha | -63.87 |
| Beta | 0.298 |
| Volatility | 109.09% |
| Current Volume | 2937.9k |
| Average Volume 20d | 1001.9k |
| Stop Loss | 1.7 (-8.6%) |
| Signal | -0.47 |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-7.88m TTM) > 0 and > 6% of Revenue (6% = 18.5m TTM) |
| FCFTA 0.09 (>2.0%) and ΔFCFTA -28.27pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -13.22% (prev 33.12%; Δ -46.34pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.09 (>3.0%) and CFO 30.0m > Net Income -7.88m (YES >=105%, WARN >=100%) |
| Net Debt (505.8m) to EBITDA (80.0m) ratio: 6.32 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.82 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (161.7m) change vs 12m ago 1.70% (target <= -2.0% for YES) |
| Gross Margin 64.59% (prev 99.49%; Δ -34.90pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 83.55% (prev 101.2%; Δ -17.70pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 2.25 (EBITDA TTM 80.0m / Interest Expense TTM 34.8m) >= 6 (WARN >= 3) |
Altman Z'' -18.39
| (A) -0.12 = (Total Current Assets 191.8m - Total Current Liabilities 232.5m) / Total Assets 342.9m |
| (B) -4.99 = Retained Earnings (Balance) -1.71b / Total Assets 342.9m |
| warn (B) unusual magnitude: -4.99 — check mapping/units |
| (C) 0.21 = EBIT TTM 78.1m / Avg Total Assets 369.3m |
| (D) -2.63 = Book Value of Equity -1.71b / Total Liabilities 651.1m |
| Total Rating: -18.39 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 50.94
| 1. Piotroski 2.0pt = -3.0 |
| 2. FCF Yield 3.66% = 1.83 |
| 3. FCF Margin 9.70% = 2.43 |
| 4. Debt/Equity -1.94 = -2.50 |
| 5. Debt/Ebitda 6.32 = -2.50 |
| 6. ROIC - WACC (= 14.77)% = 12.50 |
| 7. RoE 2.51% = 0.21 |
| 8. Rev. Trend -62.28% = -4.67 |
| 9. EPS Trend -67.20% = -3.36 |
What is the price of IRWD shares?
Over the past week, the price has changed by +14.11%, over one month by +20.00%, over three months by +147.83% and over the past year by -55.61%.
Is Ironwood Pharmaceuticals a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of IRWD is around 1.39 USD . This means that IRWD is currently overvalued and has a potential downside of -25.27%.
Is IRWD a buy, sell or hold?
- Strong Buy: 0
- Buy: 0
- Hold: 4
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the IRWD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 1.1 | -40.9% |
| Analysts Target Price | 1.1 | -40.9% |
| ValueRay Target Price | 1.5 | -21% |
IRWD Fundamental Data Overview November 04, 2025
P/E Forward = 12.3305
P/S = 1.0109
P/B = 2.5899
P/EG = -0.26
Beta = 0.298
Revenue TTM = 308.5m USD
EBIT TTM = 78.1m USD
EBITDA TTM = 80.0m USD
Long Term Debt = 385.0m USD (from longTermDebt, last quarter)
Short Term Debt = 205.8m USD (from shortTermDebt, last quarter)
Debt = 598.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 505.8m USD (from netDebt column, last quarter)
Enterprise Value = 817.7m USD (311.9m + Debt 598.7m - CCE 92.9m)
Interest Coverage Ratio = 2.25 (Ebit TTM 78.1m / Interest Expense TTM 34.8m)
FCF Yield = 3.66% (FCF TTM 29.9m / Enterprise Value 817.7m)
FCF Margin = 9.70% (FCF TTM 29.9m / Revenue TTM 308.5m)
Net Margin = -2.56% (Net Income TTM -7.88m / Revenue TTM 308.5m)
Gross Margin = 64.59% ((Revenue TTM 308.5m - Cost of Revenue TTM 109.3m) / Revenue TTM)
Gross Margin QoQ = 99.45% (prev 98.84%)
Tobins Q-Ratio = 2.38 (Enterprise Value 817.7m / Total Assets 342.9m)
Interest Expense / Debt = 1.40% (Interest Expense 8.36m / Debt 598.7m)
Taxrate = 37.61% (14.2m / 37.8m)
NOPAT = 48.7m (EBIT 78.1m * (1 - 37.61%))
Current Ratio = 0.82 (Total Current Assets 191.8m / Total Current Liabilities 232.5m)
Debt / Equity = -1.94 (negative equity) (Debt 598.7m / totalStockholderEquity, last quarter -308.2m)
Debt / EBITDA = 6.32 (Net Debt 505.8m / EBITDA 80.0m)
Debt / FCF = 16.90 (Net Debt 505.8m / FCF TTM 29.9m)
Total Stockholder Equity = -313.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -2.30% (Net Income -7.88m / Total Assets 342.9m)
RoE = 2.51% (negative equity) (Net Income TTM -7.88m / Total Stockholder Equity -313.7m)
RoCE = 109.5% (EBIT 78.1m / Capital Employed (Equity -313.7m + L.T.Debt 385.0m))
RoIC = 17.77% (NOPAT 48.7m / Invested Capital 274.1m)
WACC = 3.01% (E(311.9m)/V(910.5m) * Re(7.11%) + D(598.7m)/V(910.5m) * Rd(1.40%) * (1-Tc(0.38)))
Discount Rate = 7.11% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 1.81%
[DCF Debug] Terminal Value 70.99% ; FCFE base≈76.5m ; Y1≈51.4m ; Y5≈24.6m
Fair Price DCF = 2.96 (DCF Value 480.5m / Shares Outstanding 162.4m; 5y FCF grow -38.30% → 3.0% )
EPS Correlation: -67.20 | EPS CAGR: -31.72% | SUE: -0.77 | # QB: 0
Revenue Correlation: -62.28 | Revenue CAGR: -8.44% | SUE: 1.91 | # QB: 1
Additional Sources for IRWD Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle